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Synergistic oligodeoxynucleotide strongly
promotes CpG-induced interleukin-6
production
Shireen Nigar1,2†, Yoshinari Yamamoto1,3†, Takuma Okajima4†, Suguru Shigemori5,6, Takashi Sato7,
Tasuku Ogita8 and Takeshi Shimosato6,7,9*
Abstract
Background: Bacterial genomes span a significant portion of diversity, reflecting their adaptation strategies; these
strategies include nucleotide usage biases that affect chromosome configuration. Here, we explore an immuno-
synergistic oligodeoxynucleotide (iSN-ODN, named iSN34), derived from Lactobacillus rhamnosus GG (LGG)
genomic sequences, that exhibits a synergistic effect on immune response to CpG-induced immune activation.
Methods: The sequence of iSN34 was designed based on the genomic sequences of LGG. Pathogen-free mice were
purchased from Japan SLC and maintained under temperature- and light-controlled conditions. We tested the effects
of iSN34 exposure in vitro and in vivo by assessing effects on mRNA expression, protein levels, and cell type in murine
splenocytes.
Results: We demonstrate that iSN34 has a significant stimulatory effect when administered in combination with CpG
ODN, yielding enhanced interleukin (IL)-6 expression and production. IL-6 is a pleotropic cytokine that has been shown
to prevent epithelial apoptosis during prolonged inflammation.
Conclusions: Our results are the first report of a bacterial-DNA-derived ODN that exhibits immune synergistic activity.
The potent over-expression of IL-6 in response to treatment with the combination of CpG ODN and iSN34 suggests a
new approach to immune therapy. This finding may lead to novel clinical strategies for the prevention or treatment of
dysfunctions of the innate and adaptive immune systems.
Keywords: LGG, CpG-ODN, iSN-ODN, IL-6, Synergistic effect
Background
Nucleic acids have been shown to be particularly potent
molecular triggers of the innate immune response, not
only providing a quick response against pathogens but
also playing a role in shaping the adaptive immune re-
sponse. These nucleic acids include CpG oligodeoxynu-
cleotides (CpG ODNs) that are responsible for the
immune stimulatory effect of bacterial DNA [1]. Several
studies have demonstrated that bacterial DNA, as well as
synthetic CpG ODNs (ODNs containing unmethylated
CG dinucleotides and a phosphorothioate or chimeric
backbone that renders these molecules nuclease resistant),
have potent immunostimulatory effects [2]. In the present
study, we investigated the immune response using ODN
candidates from the Lactobacillus rhamnosus GG (LGG)
genome. Notably, the genomes of diverse bacteria share
DNA motifs that are rarely found in higher vertebrates
[3–5]. These motifs include non-methylated CG dinucleo-
tides that trigger cells expressing Toll-like receptor 9
(TLR9); this trigger results in the activation of natural
killer (NK cells), B cells, monocytes, macrophages, and
dendritic cells [2, 6–9], yielding an innate immune re-
sponse characterized by the production of Th-1 cells and
proinflammatory cytokines [10–12].
It is speculated that some intestinal bacteria exert be-
neficial effects, whereas others demonstrate deleterious
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effects. LGG chromosomal DNA has been shown to be a
potent inducer of splenic B cell proliferation, CD86/CD69
expression, and cytokine production in mouse [13] and an
efficient suppressor of allergic activity [14]. In addition,
various bacterial strains (including Lactobacillus, Lacto-
coccus, Bifidobacterium, Enterobacter cloacae, Bacteroides
fragilis, Enterococcus faecalis, and Escherichia coli) have
been shown to induce pro inflammatory mediators such
as tumor necrosis factor (TNF) -α, interleukin (IL) -6,
IL-12p70, and IL-23; these mediators may in turn be re-
sponsible for the induction and maintenance of chronic
inflammatory responses [15–18]. One component shared
among these inducing organisms is the nature of bacterial
DNA. Bacterial DNA constitutes a pathogen-associated
molecular pattern (PAMP) that is recognized by the verte-
brate immune system, leading in turn to coordinated im-
mune responses comprising both innate and acquired
immunity [19]. Unmethylated CpG dinucleotides, which
are present at high frequency in prokaryotic DNA but are
rare in eukaryotic DNA [20, 21], are considered one such
PAMP. Other research has suggested that bacterial DNA,
alone or in combination with other bacterial products,
triggers the release of IL-6, IL-12, interferon (IFN) -γ, and
immunoglobulin (Ig) M [22]. In this context, the ability of
bacterial DNA to induce IL-6 is of special interest. In fact,
overproduction of IL-6 in vivo has been shown to cause
various clinical symptoms and abnormalities (e.g., spiking
fever, skin rash, arthritis, pericarditis, hepatosplenomegaly,
and growth retardation) in laboratory models, which may
explain the manifestations observed in patients with vari-
ous inflammatory diseases, including rheumatoid arthritis
(RA) and systematic-onset juvenile idiopathic arthritis
(soJIA) [23, 24]. Here, we show that stimulation of mouse
splenocytes with the combination of CpG-ODN and an
immuno-synergistic ODN (iSN-ODN, which we have des-
ignated iSN34) derived from LGG genomic sequences
yields significant up-regulation of IL-6 expression. We fur-
ther demonstrate that this combination treatment leads to
increased IL-6 expression in vivo, and that this increased
expression enhances clinical symptoms and abnormalities.
Indeed, CpG-motif-containing ODNs are widely studied
as promising adjuvants for vaccines against a range of dis-
eases, including infections, cancer (including kidney, skin,
breast, uterine and immune malignancies [25, 26]), and
allergies. Thus, our results are consistent with those previ-
ous studies; our observation of selective enhancement of
IL-6 expression suggests that synergistic ODNs might be
useful as vaccine adjuvants.
Methods
Animals
Pathogen-free female C57BL/6 mice (4 weeks of age)
were purchased from Japan SLC (Shizuoka, Japan) and
maintained under temperature- and light-controlled
conditions. Mice were provided with ad libitum access
to a standard diet of Labo MR Breeder (Nihon Nosan
Co., Kanagawa, Japan) and sterile water. Mice were 6 to
7 weeks of age at the start of the study.
ODNs
Endotoxin-free desalted phosphorothioated (PS) ODNs
were synthesized by Integrated DNA Technologies, Inc.
(Coralville, IA, USA). Each of the PS-ODNs was recon-
stituted in endotoxin-free water and passed through a
0.22-μm pore microfilter (Nihon Millipore K.K., Tokyo,
Japan) prior to use. Mouse splenocytes were treated with
equimolar amounts of CpG ODN 1555 [27], control
ODN 1612 [28], CpG ODN 1585 [29], CpG ODN 2395
[30], or MsST (defined below) [31] (Table 1).
Cells and cell culture
Splenocytes were prepared using standard methods
[32, 33]. and were then cultured in triplicate or quadru-
plicate wells of a 24-well plate (Nalge Nunc International
K.K., Tokyo, Japan) at 2 × 106 cells/well in volumes of
1 mL/well of RPMI 1640 medium (Sigma-Aldrich) supple-
mented with 10% fetal calf serum (Sigma-Aldrich), 100 U/
mL penicillin, 100 μg/mL streptomycin, 25 mM HEPES,
1.0 mM sodium pyruvate, nonessential amino acids, and
0.0035% 2-mercaptoethanol (2-ME).
qPCR analysis
For analysis of gene expression, total RNA was isolated
from ODN-stimulated mouse splenocytes and treated
with DNase I (Macherey-Nagel GmbH & Co., Duren,
Germany) for 15 min at room temperature; the nuclease
was then heat-inactivated by incubation of the mixtures
at 70 °C for 15 min [29, 34–36]. Thereafter, cDNA was
prepared by reverse transcription from 1 μg of total
RNA per sample using the prime Script® RT reagent kit
(TaKaRa Bio, Inc., Tokyo, Japan). Equal volumes of
cDNA were used for quantification of various cytokine
cDNAs via real-time quantitative PCR (qPCR) using a
Thermal Cycler Dice® Real Time System (TaKaRa Bio,
Inc., Tokyo, Japan). The qPCR analyses were performed
with SYBR Premix Ex Taq (TaKaRa Bio) using gene-
specific primers, as described previously [32]. Primers
Table 1 ODN sequences
Name 5’-sequence-3’ Ref.
Ctr(ODN1612) GaCaTaAaGaAaGaCaTaTaAaGaGaCaT [28]
CpG-A(1585) GaGGGTCAACGTTGAGaGaGaGaGaG [29]
CpG-B(1555) GaCaTaAaGaAaCaGaTaTaAaGaCaGaT [27]
CpG-B(MsST) CaAaGaGaAaCaGaTaTaGaTaAaTaCaAaCaTaGaAaA [31]
CpG-C(2395) TaCaGaTaCaGaTaTaTaTaCaGaGaCaGaCaGaCa GaCaCaG [30]
iSN34 TaTaCaCaTaAaAaGaCaTaTaGaAaGaGaCaCaT This study
aPhosphorothioate bond
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for the β-actin- and IL-6-encoding genes were purchased
from TaKaRa Bio. As a control, poly (A)+ RNA samples
were used as templates to check for the presence of con-
taminating genomic DNA. Each pair of gene-specific
primers included one primer designed to span an exon-
intron junction, and the other designed to span the
actual exon-intron boundary. The sensitivity of the reac-
tion and amplification of contaminating products, such
as self-annealed primers, were evaluated by amplifying
serial dilutions of cDNA. For cross-sample comparison
of results obtained following various treatments, levels
of cytokine-encoding mRNA were first normalized to
those of β-actin-encoding mRNA. Data are shown as the
mean + standard deviation (SD) of one experiment rep-
resentative of three independent experiments that
yielded similar results.
Wash-out assay
Splenocytes were prepared using standard methods [35].
Cells were cultured in a 24-well plate (Nalge Nunc Inter-
national K.K., Tokyo, Japan) at 1 × 107 cells/well in vol-
umes of 1 mL/well of complete RPMI 1640 medium
(Sigma-Aldrich) supplemented with 10% fetal calf serum,
100 U/mL penicillin, 100 μg/mL streptomycin, 25 mM
HEPES, 1.0 mM sodium pyruvate, nonessential amino
acids, and 0.0035% 2-ME. Cells were incubated in the
presence of 3 μM iSN34 for 24 h at 37 °C in a 5% CO2
environment. Cells were then washed with fresh medium
to remove the iSN34. Cells were resuspended in fresh
medium supplemented with 3 μM CpG-B (ODN 1555)
for 6 h and cytokine expression was detected by qPCR
as described above. Data are shown as the mean + SD of
one experiment representative of three independent ex-
periments that yielded similar results.
Cytokine quantification
IL-6 levels in cell culture supernatants after 48 h of vari-
ous treatments were quantified using a commercially
available ELISA kit (eBioscience Inc., San Diego, CA,
USA) according to the manufacturer’s instructions.
Intracellular staining
Splenocytes (2 × 106 cells/well) were pre-incubated for
3 h in medium supplemented with either 0.625 μM
iSN34 or an equivalent volume of water. Cells then were
washed with medium to remove the ODNs, resuspended
in medium containing 3.0 μM CpG-B (ODN 1555), and
incubated for 12 h. After stimulation, cells were cultured
for 4 h at 37 °C in RPMI 1640 medium supplemented
with 10% fetal bovine serum, 100 U/mL of penicillin,
100 μg/mL of streptomycin, 10 μg/mL of brefeldin A,
2 μg/mL of ionomycin, and 20 ng/mL of phorbol 12-
myristate 13-acetate. For intracellular staining, cells were
fixed in 4% PFA for 15 min at room temperature,
washed, and permeabilized by incubation for 15 min on
ice; cells were then further incubated with phycoerythrin-
labeled anti-mouse IL-6 antibody (Biolegend). Splenocytes
were first stained with anti-mouse IL-6 antibody for
60 min on ice. Cells were washed and the percentages of
CD19+ IL-6+ cells were determined using FACS Calibur
(BD Biosciences). Data were acquired and analyzed using
Flow Jo software. All analyses were carried out at least in
triplicate; representative results are presented.
In vivo study
In vivo experiments employed 4-week-old C57BL/6
female mice obtained and maintained as described
above. After a preliminary acclimatization period of
2 weeks, mice (6 weeks of age) were sensitized by a total
of 3 intraperitoneal (i.p.) injections (administered once
every other week) of 200 μL of phosphate-buffered saline
(PBS) + PBS, PBS (100 μL) + CpG-B (100 μg), iSN34
(20 μg) + PBS, or iSN34 (20 μg) + CpG-B (100 μg). For
this study, MsST was used as the CpG-B. MsST is a
strong immunostimulatory CpG ODN that is derived
from the lacZ gene of Streptococcus thermophilus
ATCC19258 and has an ability similar to that of the
murine prototype CpG ODN (ODN 1555) to induce in-
flammatory cytokine production and cell proliferation
[31]. Mice were subjected to euthanasia and necropsy at
1 week after the final i.p injection (i.e., at 11 weeks of
age). At sacrifice, we measured body weight, spleen
weight, and spleen length, and collected blood for fur-
ther analysis.
Statistical analysis
All statistical analyses were performed using a statistical
software package (Prism 7, GraphPad, Inc., La Jolla, CA,
USA). Two-tailed One-way ANOVA with a post-hoc
Tukey-Kramer test was used to determine the signifi-
cance of the differences in all experiments except for the
body weight trends. Body weight gain changes were ana-
lyzed by Two-way ANOVA with post-hoc Bonferroni to
compare treatment and time effects. Differences were
considered significant at p < 0.05. Values for the in vivo
experiment (spleen weight and spleen length) are pre-
sented using box and whisker plots. Other in vitro values
are presented as means + SDs of three independent
experiments (n = 9).
Results
Immune synergistic activity of LGG ODN and expression
of IL-6 mRNA by murine immune cells
In this study, we analyzed the synergistic effects of ODNs
that had been designed based on LGG DNA sequences.
Candidates that were positive for synergistic effects in a
preliminary screen were subjected to confirmation of syn-
ergistic activity by assessing the stimulation of IL-6 mRNA
Nigar et al. BMC Immunology  (2017) 18:44 Page 3 of 9
expression in splenocytes (Additional file 1 Figure S1). In
order to determine the effect of iSN34 on the expression
and secretion of cytokines, we assessed IL-6 transcription
in mouse splenocytes exposed to the combination of
iSN34 + CpG-B. To determine the optimal concentration
of iSN34 for this assay, we examined IL-6 mRNA accumu-
lation in the presence of iSN34 at concentrations ranging
from 0.01 to 10 μM. As shown in Fig. 1a, iSN34 (in the
presence of CpG-B) exhibited dose-dependent stimulation
of IL-6 expression at iSN34 concentrations of 0.01 to
2.5 μM and the highest concentration of iSN34 deter-
mined at 0.63 μM. Next, we compared the activity of
iSN34 (0.63 μM) when combined with CpG-A (ODN
1585), CpG-B (ODN 1555), CpG-C (ODN 2395), or nega-
tive control (ODN 1612) ODN. As shown in Fig. 1b,
iSN34 exhibited synergy in the induction of IL-6 mRNA
expression when combined with A-type, B-type, or C-type
CpG ODNs, while the combination of iSN34 and C-type
CpG ODN did not yield significant induction of IL-6
mRNA expression. These results suggested that synergy
was strongest for the combination of iSN34 and CpG-B
(ODN 1555). To further explore the activity of iSN34, we
also examined the molecule’s effect on murine splenocytes
in a wash-out assay. The culture was exposed to 3 μM
iSN34 + CpG-B or control (water) for 24 h to monitor the
immune synergistic activity after iSN34 removal. Interest-
ingly, as shown in Fig. 1c, immune synergistic activity was
maintained in splenocytes after iSN34 was removed from
the culture, such that IL-6 mRNA levels were effectively
unchanged after wash-out of the ODNs.
Induction of IL-6 production by exposure to low-
concentration iSN34
We next investigated the secretion of IL-6 by murine
splenocytes grown for 48 h in the presence of different
concentrations of iSN34 (0.01 to 10 μM) + CpG-B; in
this experiment, IL-6 levels in the spent medium were
detected by ELISA. The results showed that the secre-
tion of IL-6 was elevated in a dose-dependent fashion
following iSN34 exposure, with peak IL-6 secretion de-
tected in the presence of 0.63 μM iSN34 (Fig. 2). This
result indicated that a low concentration of iSN34 can
induce IL-6 production.
Enhancement of the IL-6+ subpopulation in murine
splenocytes
Next, we sought to investigate the effect of iSN34 expos-
ure on a specific subpopulation of the splenocytes. Specif-
ically, we used flow cytometry to classify the identity of
IL-6+ mouse splenocyte cells following stimulation of the
CpG-induced immune reaction by the synergistic ODN.
We observed that the population of CD19+ IL-6+ cells was
increased following induction with iSN34 + CpG-B
(Fig. 3a). As shown in Fig. 3a, the percentage of CD19+
Fig. 1 iSN34 was used to determine the optimal concentration of ODNs. a
Mouse splenocytes were pre-incubated in medium for 3 h prior to exposure
to iSN34 (at 0.01, 0.04, 0.16, 0.63, 2.5, or 10 μM) + CpG-B (ODN1555; at
equimolar levels) or to ODN 1612 (control) for 6 h. Accumulation of IL-6
mRNA was determined by qPCR. Results are shown as the ratio of IL-6
mRNA levels for stimulated (iSN + CpG-B) versus ODN 1612-treated cells. b
The synergistic effects of iSN34 (0.63 μM) were assessed in combination with
CpG-A (ODN 1585), CpG-B (ODN 1555), CpG-C (ODN 2395), and Ctr 1612
(Control ODN). cMouse splenocytes (1 × 107 cells/mL) were pre-incubated
in medium for 3 h prior to exposure to 3 μM ODN 1612 or iSN34 for 24 h.
Cells then were washed with medium (to remove the ODNs) and
resuspended in medium with 3 μM CpG-B (ODN 1555) for 6 h. Results
are shown as IL-6 mRNA expression (normalized to β-actin-encoding
mRNA; see qPCR method) in stimulated cells in the wash-out assay. All
assays were carried out at least three independent times in triplicate.
Similar results were obtained from at least three different mice. Values
are presented as mean + SD of three independent experiments, each
performed in triplicate (n = 9). Values with different letters (i.e., a, b, c, d,
and e) were significantly different. ****p < 0.0001 vs. iSN34 (0 μM)
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cells were significantly elevated in the cells treated with
iSN34 + CpG-B. Additionally, this stimulation rendered
the CD19+ IL-6+ subpopulation a significantly larger frac-
tion of the total cell population (Fig. 3b). Thus, the syner-
gistic effects of iSN34 + CpG-B reflected increased IL-6
expression in CD19+ B-lymophocytes.
Effect of i.p. injection of iSN34 + CpG
We next extended our analysis of the synergistic effects
of iSN34 + CpG by testing this treatment in vivo
(Fig. 4a). All four groups of mice (n = 4/group; injected
i.p. with PBS + PBS, PBS + CpG-B, iSN34 + PBS, or
iSN34 + CpG-B) exhibited typical weight gain during
the course of the study, and there was no significant dif-
ference among the 4 groups in terms of terminal body
weight (Additional file 2 Figure S2). We did, however,
note hypertrophy (splenomegaly) of the spleen in mice
treated with iSN34 + CpG-B compared to the spleens of
the other groups (Additional file 3 Figure S3); these
effects were significant whether assessed as spleen
weight (Fig. 4b) or length (Fig. 4c). Our findings suggest
that the combined use of iSN34 and CpG-B may find
application in modifying the innate immune response.
Discussion
Our study revealed that iSN34 exhibits immune
synergistic effects when combined with CpG-ODN. The
activity of iSN34 was associated with multiple types of
Fig. 2 iSN34 with CpG-B enhances IL-6 production. Supernatants
from stimulated cells were collected and IL-6 protein levels were
measured by ELISA. Mouse splenocytes were harvested 48 h later
and intracellular IL-6 protein levels were determined by ELISA. All
assays were carried out at least three independent times in triplicate.
Similar results were obtained from at least three different mice.
Values are presented as mean + SD of three independent experiments,
each performed in triplicate (n = 9). Values with different letters (i.e., a,
b, c, d, e, and f) were significantly different. ****p < 0.0001 vs.
iSN34(0 μM). ND; not detectable
Fig. 3 Representative flow cytometry plots. Dot plot of forward-angle
versus right-angle light-scattering properties; the oval marks indicate
the electronic windows used for analysis of fluorescence data for
lymphocyte precursors; the rectangular boxes indicate the electronic
windows used for analysis of fluorescence data for monocyte precursors
with percentages. a A quadrant has been set to delineate the CD19 and
IL-6 cells. Murine splenocytes were stimulated with water + water, water
+ CpG-B, iSN34 + water, or iSN34 + CpG-B for 12 h, and then sorted into
CD19+ IL-6+ cells. b Mean percentage of IL-6+ CD19+ cells in the total
population was determined in each group. Similar results were obtained
from at least three different mice. Values are presented as mean + SD of
three independent experiments, each performed in triplicate (n = 9).
Values with different letters (i.e., a, b, c, and d) were significantly
different (p < 0.01)
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CpG-ODNs. We showed the synergistic activity of
iSN34 + CpG at the level of IL-6 mRNA accumulation,
IL-6 protein secretion, and IL-6+ cell production following
in vitro exposure of cultured splenocytes. Among the
tested ODNs, only iSN34 exhibited these effects, which
were observed only when combined with CpG ODN.
Previous work has shown that CpG ODN is an extremely
potent stimulator of dendritic cells and macrophages,
causing the induction of Th-1-associated cytokines such
as IL-6 and IL-12 [37]. In the present work, the ODN
iSN34 was able (in combination with CpG) to stimulate
the production of IL-6, suggesting that iSN34 would be a
highly effective adjuvant for Th-1-mediated vaccines.
Thus, our results indicated that the combination of
iSN34 + CpG strongly induces the expression of IL-6,
and therefore might be useful for the prevention or
treatment of diseases associated with inflammatory dis-
orders, including RA, inflammatory bowel disease (IBD),
multiple sclerosis, systematic-onset juvenile chronic
arthritis (JCA), osteoporosis, and psoriasis [38–41].
However, other work has shown that IL-6 acts as a po-
tent stimulator of B-cell proliferation [42], plasma cell
survival [43], and antibody production [44], effects that
might be at odds with the prevention or treatment of
some diseases. Further work will be needed to address
the combination of these distinct effects.
We observed that iSN34 exhibited greater synergy
when combined with CpG-B (Fig. 1b). On the other
hand, iSN34 did not display synergy in combination with
CpG-C. These results indicated that CpG-B is the appro-
priate synergistic inducer for use with iSN34. Our stud-
ies also showed that co-administration of iSN34 + CpG
ODN had synergistic effects in a wash-out assay. Specif-
ically, we demonstrated that splenocytes pretreated with
iSN34 maintain the ability to stimulate the immune re-
sponse even after the iSN34 is washed out, suggesting
that the immune synergistic effect of iSN34 may be me-
diated via stimulation of cell signaling. Assessment of
the immune synergistic effect of iSN34 + CpG-B by
measuring IL-6 protein secretion (via ELISA) demon-
strated that 0.63 μM iSN34 yielded peak synergistic effi-
cacy under our experimental conditions.
CD19 is one of the most reliable biomarkers for B cells
that can receive positive stimuli from a variety of cyto-
kines, including IFN, IL-4 and IL-6; such stimulation
leads to proliferation, differentiation, cytokine produc-
tion, and other effector functions [45]. In the present
work, B cells exposed to the combination of CpG and
iSN34 showed significant up-regulation of CD19 expres-
sion compared to controls. To clarify whether specific
subpopulations of cells were selectively activated by
iSN34, we further characterized IL-6producing spleno-
cytes using flow cytometry. This flow cytometric analysis
revealed that the proportion of IL-6secreting CD19+
B-cells in the spleen increased over two-fold in mice
treated with iSN34 + CpG-B, compared to the levels
seen in the control group (Fig. 3c). These findings could
be relevant for the study of inflammation.
Fig. 4 Cellular changes in spleens of mice following the in vivo trial. a Schematic design of the in vivo experiment, performed in female C57BL/6
mice. Six-week-old mice were sensitized by a total of three i.p. injections (administered once every other week) with 200 μL of PBS + PBS, PBS
(100 μL) + CpG-B (100 μg), iSN34 (20 μg) + PBS, or iSN34 (20 μg) + CpG-B (100 μg). Mice were euthanized at 11 weeks of age. b Spleen weight
(mg). c Spleen length (cm). Results in panels b and c are presented using box and whisker plots. The central bar in each box indicates the median, with
boxes extending to the 25th and 75th percentile values; whiskers extend to the minimum and maximum values. Values with different letters (i.e., a, b,
c, and d) were significantly different (p < 0.01)
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We also found that co-administration of iSN34 + CpG-
B in vivo in healthy mice was sufficient to cause expansion
of this cell type, yielding increased spleen weight and
length. Notably, this treatment did not result in significant
changes in terminal body weight compared to control
groups, suggesting that iSN34 was not associated with
gross toxicity (as might be implied by weight loss or at-
tenuation of weight gain). We did, however, detect hyper-
trophy of the spleen in mice sensitized by i.p. injection
with iSN34 + CpG-B. In previous work, we demonstrated
that CpG-B is involved in activating the innate immune
response and induces splenomegaly [29, 46]. Indeed,
splenomegaly has been considered an important com-
plication of acute and chronic disease for more than
100 years [47–49].
Notably, iSN34 does not provide significant synergistic
induction of inflammatory cytokines (TNF-α, IFN-γ)
other than IL-6 (data not shown). Given this observa-
tion, combined therapies incorporating iSN34 may sig-
nificantly complement and further enhance the positive
effects of mucosal immunity. In summary, our study
demonstrated that iSN34 acts synergistically in combin-
ation with CpG ODN in the induction of IL-6. This
multifunctional cytokine was originally identified as a
T-cell-derived factor, and has subsequently been shown
to induce the differentiation of activated B-cells into
antibody-producing cells with biological activities that
include the regulation of immune response, inflamma-
tion, and hematopoiesis [23]. This synergy may represent
a new modality for the treatment of systematic inflam-
matory disorders.
Conclusions
The new insights provided by this study suggest a new
concept of synergistic ODN activity distinct from that
described in previous ODN studies. However, the impli-
cations of this synergy for clinical symptoms or disease
risk are unknown. These facts suggest that this immune
synergy represents a wide-open research field with good
scientific prospects, and could yield improvements in
the prevention and treatment of immune disorders.
However, further preclinical and clinical investigations
will be needed to understand how specific targeting of
the IL-6 pathway can be applied in disease treatment.
Additional files
Additional file 1: Figure S1. Analysis of IL-6 mRNA expression in
mouse splenocytes, as assessed by qPCR. Mouse splenocytes (2 × 106
cells/mL) were pre-incubated in medium for 3 h prior to exposure to
3 μM iSN candidates (No. 1–50), to CpG-B (ODN 1555), or to ODN 1612
(control) for 6 h. The results are presented as the mean + SD of at least
three independent experiments, each performed in triplicate. **** p < 0.0001
vs. [Ctr (1612) + CpG-B] (blue). Red: [iSN34 + CpG-B], Orange: [iSN35 + CpG-B].
(TIFF 16522 kb)
Additional file 2: Figure S2. Body weight trends in female C57BL/6
mice (from 6 to 11 weeks of age) during treatment with iSN34 + CpG-B
or control regimens. Body weights were measured once weekly. Data
presented are the average weight per group. Data are presented as
mean ± SE. (TIFF 2046 kb)
Additional file 3: Figure S3. Changes in spleen size in mice after
administration of iSN34 + CpG-B or control regimens. The picture shows
representative spleens from one animal of each of the four groups:
PBS + PBS, PBS + CpG-B, iSN34 + PBS, and iSN34 + CpG-B. (TIFF 5405 kb)
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